Bisphosphonates and breast cancer incidence and recurrence

Breast Disease

Volumn 33, Issue 2, 2011, Pages 93-101

  Chlebowski, Rowan T ^a   Col, Nananda ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

adjuvant therapy; anticancer; Bisphosphonates; breast cancer chemoprevention; early breast cancer

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; EXEMESTANE; FLUOROURACIL; GOSERELIN; LETROZOLE; METHOTREXATE; PLACEBO; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ARTICLE; BONE DENSITY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; EARLY CANCER; ESOPHAGITIS; FEMUR FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; JAW OSTEONECROSIS; KIDNEY DISEASE; NEPHROTOXICITY; OSTEOLYSIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CLODRONIC ACID; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; INCIDENCE;

EID: 84858263847     PISSN: 08886008     EISSN: 15581551     Source Type: Journal    
DOI: 10.3233/BD-2010-0324     Document Type: Article

References (53)

1. R.E. Coleman, Risks and benefits of bisphosphonates, Br J Cancer 98 (2008), 1736-1740. (Pubitemid 351748847)
2. R.T. Chlebowski, J. Cuzick, D. Amakye, I. Bauerfeind, A. Buzdar, S. Chia, B. Cutuli, R. Linforth, N. Maass, S. Noguchi, A. Robidoux, S.Verma and P. Hadji, Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer, Breast 18 (2009), S1-S11.
3. J.J. Body, I.J, Diel, M. Lichinitzer, A. Lazarev, M. Pecherstor-fer, R. Bell, D. Tripathy and B Bergstrom, Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies, Br J Cancer 90 (2004), 133-137.
4. J.E. Lester, D. Dodwell, O.P. Purohit, S.A. Gutcher, S.P. Ellis, R. Thorpe, J.M. Horsman, J.E. Brown, R.A. Hannon and R.E. Coleman, Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer, Clin Cancer Res 14 (2008), 6336-6342.
5. C. Markopoulos, E, Tzoracoleftherakis, A. Polychronis, B. Venizelos, U. Dafni, G, Xepapadakis, J. Papadiamantis, V. Zobolas, J. Misitzis, K. Kalogerakos, A. Sarantopoulou, N. Siasos, D. Koukouras, Z. Antonopoulou, S. Lazarou and H. Gogas, Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial, Breast Cancer Res 12 (2010), R24.
6. C.H. Van Poznak, R.A. Hannon, J.R. Mackey, M. Campone, J.P. Apffelstaedt, G. Clack, D. Barlow, A. Makris and R. East-ell, Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial, J Clin Oncol 28 (2010), 967-975.
7. A. Brufsky, N. Bundred, R. Coleman R, R. Lambert-Falls, R. Mena, P. Hadji, L Jin, N. Schenk, S. Ericson and E.A. Perez, Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole, Oncologist 13 (2008), 503-514. (Pubitemid 351872868)
8. M. Gnant, B. Mlineritsch, G. Luschin-Ebengreuth, F. Kain-berger, H. Kässmann, J.C. Piswanger-Sölkner, M. Seifert, F. Ploner, C. Menzel, P. Dubsky, F. Fitzal V. Bjelic-Radisic, G. Steger, R. Greil, C. Marth, E. Kubista, H. Samonigg, P, Wohlmuth, M. Mittlböck and R. Jakesz, Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy, Lancet Oncol 9 (2008), 840-849.
9. S.L. Hines, J.A. Sloan, P.J. Atherton, E.A. Perez, S.R. Dakhil, D.B. Johnson, P.S. Reddy, R.J. Dalton, B.I. Mattar and C.L. Loprinzi, Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy, Breast 19 (2010), 92-96.
10. G.K. Ellis, H.G. Bone, R.T. Chlebowski, D. Paul, S. Spadafo-ra, J. Smith, M. Fan and S Jun, Randomized trial of denosum-ab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer, J Clin Oncol 26 (2008), 4875-4882.
11. M.C. Winter, I. Holen and R.E. Coleman, Exploring the anti-tumour activity of bisphosphonates in early breast cancer, Cancer Treat Rev 34 (2008), 453-475.
12. J. Green and A. Lipton, Anticancer properties of zoledronic acid, Cancer Invest 28 (2010), 944-957.
13. M. Gnant, B. Mlineritsch, W. Schippinger, G. Luschin-Ebengreuth, S. Pöstlberger, C Menzel, R Jakesz, M. Seifert, M. Hubalek, V. Bjelic-Radisic, H Samonigg, C Tausch, H Ei-dtmann, G Steger. W. Kwasny, P. Dubsky, M. Fridrik, F. Fitzal, M. Stierer, E. Rücklinger and R. Grei, Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med 360 (2009), 679-691.
14. R. Coleman, H. Thorpe and D. Cameron, Adjuvant Treatment With Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04). Presented at: 33nd Annual San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, TX, abstract S4-S5.
15. I. Elomaa, C. Blomqvist, L. Porkka, C. Lamberg-Allardt and G.H. Borgström, Treatment of skeletal disease in breast cancer: a controlled clodronate trial, Bone 8 (1987), S53-S56. (Pubitemid 18047657)
16. I.J. Diel, E.F. Solomayer, S.D. Costa, C. Gollan, R. Goern-er, D. Wallwiener, M. Kaufmann and G. Bastert, Reduction in new metastases in breast cancer with adjuvant clodronate treatment, N Engl J Med 339 (1998), 357-363. (Pubitemid 28363797)
17. I.J. Diel, A. Jaschke, E.F. Solomayer, C. Gollan, G. Bastert, C. Sohn and F. Schuetz, Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up, Ann Oncol 19 (2008), 2007-2011.
18. T. Saarto, L. Vehmanen, P. Virkkunen and C. Blomqvist, Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients, Acta Oncol 43 (2004), 650-656. (Pubitemid 39563937)
19. T. Powles, S. Paterson, J.A. Kanis, E. McCloskey, S. Ashley, A. Tidy, K. Rosenqvist, I. Smith, L. Ottestad, S. Legault, M. Pajunen, A. Nevantaus, E. Männistö, A. Suovuori, S. At-ula, J. Nevalainen and L. Pylkkänen, Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer, J Clin Oncol 20 (2002), 3219-3224. (Pubitemid 34831518)
20. T. Powles, A. Paterson, E. McCloskey, P. Schein, B. Schef-fler, A. Tidy, S. Ashley, I. Smith, L. Ottestad and J. Kanis, Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer ISRCTN83688026, Breast Cancer Res 8 (2006), R13.
21. E.P. Mamounas, NSABP breast cancer clinical trials: recent results and future directions, Clin Med Res 1 (2003), 309-326.
22. M. Aapro, Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program, Breast 15 (2006), S30-S40. (Pubitemid 43264339)
23. A.M. Brufsky, L.D. Bosserman, R.R. Caradonna, B.B. Haley, C.M. Jones, H.C. Moore, L. Jin, G.M. Warsi, S.G. Er-icson and E.A. Perez, Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results, Clin Breast Cancer 9 (2009), 77-85.
24. H. Eidtmann, R. de Boer, N. Bundred, A. Llombart-Cussac, N. Davidson, P. Neven, G. von Minckwitz, J. Miller, N. Schenk and R. Coleman, Efficacy of zoledronic acid in post-menopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study, Ann Oncol 21 (2010), 2188-2194.
25. R. de Boer, N. Bundred and H. Eidtmann, The effect of zole-dronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: The ZO-FAST study 5-year final follow-up poster. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Poster P5-11-01.
26. R. Coleman, N. Bundred, R. de Boer, A. Llombart, I. Campbell, P. Neven, C. Barrios, R. Dias, J. Miller and A. Brufsky, Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at: 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, TX, abstract 4082.
27. A. Tevaarwerk, J.A. Stewart, R. Love, N.C. Binkley, S. Black, J. Eickhoff and D.L. Mulkerin, Randomized trial to assess bone mineral density effects of zoledronic acid in postmenopausal women with breast cancer, J Clin Oncol 25 (2007), 711s, abstract 19558.
28. D. Mauri, A. Valachis, N.P. Polyzos, L. Tsali, D. Mavroudis, V. Georgoulias and G. Casazza, Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials, J Natl Compr Canc Netw 8 (2010), 279-286.
29. N. Schenk, A. Llombart, A. Frassoladti, P. Neven, G. Jerusalem, I. Deleu, J. Meois, M. Maerevoet, J. Miller and R. Dias, The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let). Presented at: EC-CO 14, the European Cancer Conference, September 23-27, 2007, Barcelona, Spain, abstract 2008.
30. R.T. Chlebowski and N.F. Col, Bisphosphonates and breast cancer prevention, Anticancer Agents in Med Chem (2011), Epub ahead of print.
31. R.E. Coleman, M.C. Winter, D. Cameron, R. Bell, D. Dod-well, M.M. Keane, M. Gil, D. Ritchie, J.L. Passos-Coelho, D. Wheatley, R. Burkinshaw, S.J. Marshall and H. Thorpe, The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer, Br J Cancer 102 (2010), 1099-1105.
32. M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth, S. Poestlberger, P.C. Dubsky, R. Jakesz, C.F. Singer, H. Eidt-mann and R. Greil, Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockage: long-term results from ABCSG-12, J Clin Oncol 29 (2011); (supl, absts 520).
33. Z. Chen, L. Arendell, M. Aickin, J. Cauley, C.E. Lewis and R.T. Chlebowski, Hip bone density predicts breast cancer risk independently of Gail Score: results from the Women's Health Initaitive, Cancer 113 (2008), 907-915.
34. R.T. Chlebowski, Z. Chen, J.A. Cauley, G. Anderson, R.J. Rodabough, A. McTiernan, D.S. Lane, J.E. Manson, L. Snet-selaar, S. Yasmeen, M.J. O'Sullivan, M. Safford, S.L. Hendrix and R.B. Wallace, Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28 (2010), 3582-3590.
35. J. Robbins, A.K. Aragaki, C. Kooperberg, N. Watts, J. Wactawski-Wende, R.D. Jackson, M.S. LeBoff, C.E. Lewis, Z. Chen, M.L. Stefanick and J. Cauley, Factors associated with 5-year risk of hip fracture in postmenopasual women, JAMA 298 (2007), 2389-2398. (Pubitemid 350190780)
36. P. Vestergaard, L. Fischer, M. Mele, L. Mosekilde and P. Christiansen, Use of bisphosphoante and risk of breast cancer, Calcif Tissue Int 88 (2011), 255-262.
37. P.A. Newcomb, A. Trentham-Dietz and J.M. Hampton, Bis-phosphonates for osteoporosis treatment are associated with reduced breast cancer risk, Br J Cancer 102 (2010), 799-802.
38. G. Rennert, M. Pinchev and H.S. Rennert, Use of bisphospho-nates and risk of postmenopausal breast cancer, J Clin Oncol 28 (2010), 3577-3581.
39. A.O. Hoff, B. Toth, M. Hu, G.N. Hortobagyi and R.F. Gagel, Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients, Ann N Y Acad Sci 1218 (2011), 47-54.
40. J. Schilcher, K. Michaelsson and P. Aspenberg, Bisphospho-ante use and atypical fractures of the femoral shaft, N Engl J Med 364 (2011), 1728-1737.
41. J.E. Mortimer and S.K. Pal, Safety considerations for use of bone-targeted agents in patients with cancer, Semin Oncol 37(1) (2010), S66-S72.
42. O. Bock and D. Felsenberg, Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice, Clin Interv Aging 3 (2008), 279-297. (Pubitemid 352037868)
43. A.M. Gallagher, S. Rietbrock, M. Olson and T.P. van Staa, Fracture outcomes related to persistence and compliance with oral bisphosphonates, J Bone Miner Res 23 (2008), 1569-1575.
44. J.R. Gralow, Bisphosphonate risks and benefits: Finding a balance, J Clin Oncol 28 (2010), 4873-4876.
45. A. Ribeiro, K.R. DeVault, J.T. Wolfe and M.E. Stark, Alendronate- associated esophagitis: endoscopic and pathologic features, Gastrointest Endosc 47 (1998), 525-528. (Pubitemid 28287574)
46. D.K. Wysowski, Reports of esophageal cancer with oral bis-phosphoante use, N Engl J Med 360 (2009), 89-90.
47. J. Green, G. Czanner, G. Reeves, J. Watson, L, Wise and V. Beral, Oral bisphosphonates and risk of cancer of oesphagus, stomach, and colorectum: case-control analysis within a UK primary care cohort, BMJ 341 (2010), c4444.
48. C.R. Cardwell, C.C. Abnet, M.M. Cantwell and L.J. Murray, Exposure to oral bisphosphoantes and risk of esophageal cancer, JAMA 304 (2010), 657-663.
49. K. Visvanathan, R.T. Chlebowski, P. Hurley, N.F. Col, M. Rop-ka, D. Collyar, M. Morrow, C. Runowicz, K.I. Pritchard, K. Hagerty, B. Arun, J. Garber, V.G. Vogel, J.L. Wade, P. Brown, J. Cuzick, B.S. Kramer and S.M. Lippman, American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction, J Clin Oncol 27 (2009), 3235-3258.
50. R.L. Ward, G. Morgan, D. Dalley and P.J. Kelly, Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women, Bone Miner 22 (1993), 87-94. (Pubitemid 23272793)
51. P.J. Meunier, E. Vignot, P. Garnero, E. Confavreux, E. Paris, S. Liu-Leage, S. Sarkar, T. Liu, M. Wong and M.W. Draper, Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group, Osteoporos Int 10 (1999), 330-336. (Pubitemid 29476199)
52. P.E. Goss, J.N. Ingle, J. Ales-Martinez, A. Cheung, R.T. Chle-bowski, J. Wactawski-Wende, A. McTiernan, J. Robbins, K. Johnson, L. Martin, E. Winquist, G. Sarto, J.E. Garber, C.J. Fabian, P. Pujol, E. Maunsell, P. Farmer, K.A. Gelmon, D. Tu and H. Richardson, Exemestane for breast-cancer prevention in postmenopausal women, N Engl J Med 364 (2011), 2381-2391.
53. H.L. Neville-Webbe, M. Gnant and R.E. Coleman, Potential anticancer properties of bisphosphonates, Semin Oncol 37(1) (2010), S53-S65.